Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A recent article reads, “Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also acknowledged that psychedelics are far from mainstream, but that is an opportunity for the company to play the role of a first mover. ‘They [psychedelics] are not mainstream yet. That’s actually the opportunity. Nobody’s done that yet. We’re just now making them synthetically and making them up to pharmaceutical-grade standards,’ Mr. McKee noted.”
To view the full article, visit https://ibn.fm/EF1lb
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.